Mononitrates

  • Adam Schneeweiss

Abstract

The term “mononitrates” refers in general to the two metabolites of ISDN, namely, IS-5-MN and IS-2-MN. These metabolites are formed in the liver.

Keywords

Placebo Depression Ischemia Attenuation Cardiol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Nyberg G, Blychert L-O, Jonsson UE (1985) Pharmacokinetics of isosorbide-5-mononitrate in a controlled-release (Durules) formulation. Br J Clin Pharmacol 20: 541pGoogle Scholar
  2. 2.
    Krepp HP (1985) Langzeitehandlung der koronaren Herzerkrankung mit elantan long. In: Borchard U, Rafflenbeul W, Schrey A (eds) Mononitrat. Universitätsdruckerei und Wolf, Munich, pp 176–183Google Scholar
  3. 3.
    Ohlmeier H, Mertens HM, Mannebach H, Gleichmann U (1985) Tolerance and rebound phenomena in nitrate therapy. In: Cohn JH, Rittinghausen R (eds) Mononitrates. Springer, Berlin Heidelberg New York, pp 107–123CrossRefGoogle Scholar
  4. 4.
    Eggeling T, Osterspey A, Geppert R, Jansen W (1985) Antianginöse Wirksamkeit von retardiertem Isosorbid-5-Mononitrat bei Patienten mit koronarer Herzkrankheit. In: Borchard U, Rafflenbeul W, Schrey A (eds) Mononitrat. Universitätsdruckerei und Wolf, Munich pp 76–87Google Scholar
  5. 5.
    Akhras G, Jackson C (1986) Isosorbide-5-mononitrate as monotherapy in patients with chronic stable angina (Abstract). J Am Coll Cardiol 7–230AGoogle Scholar
  6. 6.
    Bidoggia JH, Casar JE, Hirschon AJ, Campo A, Nordaby R (1985) Beneficial effects of isosorbide-5-mononitrate on exercise performance in patients with chronic stable angina pectoris. In: Cohn JN, Rittinghausen R (eds) Mononitrates. Springer, Berlin Heidelberg New York, pp 201–214CrossRefGoogle Scholar
  7. 7.
    Uusitalo A, Keyriläinen O, Härkönen R, Penti R et al. (1988) Antianginal efficacy of a controlled release formulation of isosorbide-5-mononitrate once daily in angina patients on chronic β-blockade. Acta Med Scand 223: 219–225PubMedCrossRefGoogle Scholar
  8. 8.
    Nyberg G, Carlens P, Lindström E, Lundman T et al. (1986) The effect of isosorbide-5-mononitrate (5-ISMN) Durules on exercise tolerance in patients with exertional angina pectoris. A placebo controlled study. Eur Heart J 7: 835–842PubMedGoogle Scholar
  9. 9.
    Svendsen JH, Aldershvile J, Abildgaard U, Amtorp O (1987) Efficacy of isosorbide-5-mononitrate in angina pectoris patients. An abstract presented at the XI Scandinavian congress of cardiology, Kuopio, Finland, Aug 1987Google Scholar
  10. 10.
    Svensen JH, Aldershvile J, Amtorp O (1986) Absence of nitrate crosstolerance during slow-release isosorbide-5-mononitrate (5 MN) treatment. Acta Pharmacol Toxicol [Suppl V]: 179Google Scholar
  11. 11.
    Schiavoni G, Montenero AS, Mazzari M, Biasucci LM, Manzoli U (1985) The efficacy of IS-5-MN in patients with ischemic heart disease: a pilot study. In: Cohn JN, Rittinghausen R (eds) Mononitrates. Springer Berlin Heidelberg New York, pp 230–234CrossRefGoogle Scholar
  12. 12.
    Myberg G, Jonsson U (1986) Can tolerance development with 5-isosorbide mononitrate be avoided with a once-daily controlledrelease formulation? Acta Pharmacol Toxicol [Suppl V]: 148Google Scholar
  13. 13.
    Meffert M, Paeckelmann I-M (1987) Experience of long-term treatment and different dosage regimens of isosorbide-5-mononitrate. Drugs 33[Suppl 4]: 104–110PubMedCrossRefGoogle Scholar
  14. 14.
    Uusitalo A (1987) Long-term efficacy of a controlled release formulation of isosorbide-5-mononitrate (Imdur) in angina patients receiving β-blockers. Drugs 33[Suppl 4]: 111–117PubMedCrossRefGoogle Scholar
  15. 15.
    Rehnqvist N, Olsson G, Engvall J et al. (1987) Abrupt withdrawal of isosorbide-5-mononitrate (Imdur) after long-term treatment in stable angina pectoris. Drugs 33[Suppl 4]: 118–121PubMedCrossRefGoogle Scholar
  16. 16.
    Rennhak U, Riebesel T, Biamino G (1985) A double-blind cross-over study on the effectiveness and possible development of tolerance during long-term therapy with isosorbide-5-mononitrate or isosorbide dinitrate slow-release in coronary artery disease. In: Cohn JN, Rittinghausen R (eds) Mononitrates. Springer, Berlin Heidelberg New York, pp 147–153CrossRefGoogle Scholar
  17. 17.
    Mentzel M (1984) Ein-Jahresstudie mit Elantan bei Patienten mit koronarer Herzerkrankung — Wirksamkeit und Verträglichkeit im Rahmen einer Langzeitbehandlung. In: Hochrein H, Tauchert M, Schrey A, Weiss M (eds) Mononitrat. Universitätsdruckerei und Wolf, Munich pp 98–111Google Scholar
  18. 18.
    Heepe W (1984) Langzeittherapie der Patienten mit koronarer Herzkrankheit mit IS-5-MN retard. In: Hochrein H, Tauchert M, Schrey A, Weiss M (eds) Mononitrat. Universitätsdruckerei und Wolf, Munich, pp 172–229Google Scholar
  19. 19.
    Tauchert M, Jansen W, Osterspey A, Fuchs M, Hombach V, Hilger HH (1983) Dose dependence of tolerance during treatment with mononitrates. Z Kardiol 72[Suppl 3]: 218–228PubMedGoogle Scholar
  20. 20.
    Kenedi P (1985) Intraindividuelle Dosiswirkungsbeziehung von elantan long. In: Borchard U, Rafflenbeul W, Schrey A (eds) Mononitrat. Universitätsdruckerei und Wolf, Munich pp 108–115Google Scholar
  21. 21.
    Thadani U, Hamilton SF, Olson E et al. (1987) Duration of effects and tolerance of slow-release isosorbide-5-mononitrate for angina pectoris. Am J Cardiol 59: 756–762PubMedCrossRefGoogle Scholar
  22. 22.
    Müller G, Überbacher HJ, Glocke M (1983) Koronartherapeutische Wirksamkeit von niedrig dosiertem Isosorbide-5-Mononitrate im Vergleich zur Kombination von IS-5-MN und Metipranolol und Placebo. Med Welt 34: 321–327PubMedGoogle Scholar
  23. 23.
    Koch G, Fransson L, Karlegärd L, Sauer W, Übberbacher HJ (1985) Double-blind comparison of the effects of nifedipine and isosorbide-5-mononitrate on the circulatory response to exercise, exercise tolerance, and ST-segment depression in patients with ischemic heart disease. In: Cohn JH, Rittinghausen R (eds) Mononitrates. Springer, Berlin Heidelberg, New York pp 245–253CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • Adam Schneeweiss
    • 1
  1. 1.Tel AvivIsrael

Personalised recommendations